As of now, there is still no definitive cure for coronavirus and scientists are scrambling to find and develop a cure. Papua New Guinea is also on the search for a cure as its government has allocated $3 million to an unknown firm to find a possible COVID-19 cure.
Papua New Guinea has given $3 million to a company known as Niugini BioMed Ltd., which was established back in August. The funds will be used for research to discover a possible cure for COVID-19 from existing drugs. This report was found from leaked documents in contrast to Prime Minister James Marape saying that the country’s national executive council has not yet completed its approval process to assign a company to find a possible COVID-19 cure.
So far, a team from the University of Papua New Guinea was claimed to have looked through 30,000 known drugs all over the world to identify 10 possible COVID-19 treatments. The cabinet submission that presented the claim was also signed by Marape, will instruct the ministers, its treasury, and finance to give $10.2 million kinas or around $2.8 million. The submission also instructs its health department to collaborate with the company assigned to start running clinical trials.
“We have young and competent PNG scientists, who have presented their case to the COVID-19 controller...and our medical and science community, that they may be on to something big,” said Marape. “It may be true, or vice-versa, but I am not a prime minister to kill ingenuity, research, science, and study.”
Meanwhile, in the United States, a $375 million deal was brokered with company Eli Lilly to provide 300,000 doses of its experimental antibody drug to possibly treat COVID-19. The deal details that the company has two months to deliver the doses after being given an emergency use authorization by the Food and Drug Administration. It also gives the government an option to buy 650,000 more doses all the way through June 30, said the company.
Eli Lilly filed a request to the FDA this month for an emergency use authorization of its drug to be used on COVID-19 patients with mild to moderate cases.


Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
NASA's Artemis II Mission: First Crewed Lunar Journey Since Apollo
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Trump Administration Releases New UFO Files and Apollo Mission Records
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions
China vs. NASA: The New Moon Race and What's at Stake by 2030
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility?
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Tabletop particle accelerator could transform medicine and materials science
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 



